|
16 Jul 2025 |
Tata Chemicals
|
Consensus Share Price Target
|
925.30 |
814.38 |
- |
-11.99 |
sell
|
|
|
|
|
29 May 2025
|
Tata Chemicals
|
Geojit BNP Paribas
|
925.30
|
984.00
|
891.20
(3.83%)
|
6.34 |
Hold
|
|
|
TCL faces short-term challenges, including sluggish demand in the US and Europe and decreasing export prices in the US market, as well as downward pressure on *over or under performance to benchmark index margins due to declining soda ash prices. However, the company is well-positioned for growth, driven by its strategic emphasis on speciality products and capacity expansion plans. A recovery in volumes and margins is anticipated in the next fiscal year, led by the Indian and Kenyan markets. The UK business is expected to show signs of improvement from the second quarter, driven by its new pharmaceutical...
|
|
17 Oct 2024
|
Tata Chemicals
|
Motilal Oswal
|
925.30
|
1070.00
|
1073.85
(-13.83%)
|
Target met |
Neutral
|
|
|
TTCH’s 2QFY25 consolidated EBITDA declined 25% YoY, due to lower realizations YoY, higher freight costs and unfavorable operating leverage across geographies.
|
|
05 Aug 2024
|
Tata Chemicals
|
Motilal Oswal
|
925.30
|
980.00
|
1053.25
(-12.15%)
|
Target met |
Neutral
|
|
|
TTCH’s 1QFY25 consolidated EBITDA declined 45% YoY, due to subdued operating performance across geographies, with India/US/UK/Kenya reporting EBITDA decline of 19%/58%/84%/61% YoY.
|
|
07 May 2024
|
Tata Chemicals
|
Geojit BNP Paribas
|
925.30
|
979.00
|
1063.55
(-13.00%)
|
Target met |
Sell
|
|
|
|
|
29 Apr 2024
|
Tata Chemicals
|
Motilal Oswal
|
925.30
|
980.00
|
1099.50
(-15.84%)
|
Target met |
Neutral
|
|
|
Tata Chemicals (TTCH)’s 4QFY24 consolidated EBITDA declined 54% YoY, primarily due to a subdued operating performance across geographies with India/US/UK/Kenya reporting 26%/68%/72%/57% decline YoY.
|
|
06 Feb 2024
|
Tata Chemicals
|
Motilal Oswal
|
925.30
|
900.00
|
991.95
(-6.72%)
|
Target met |
Neutral
|
|
|
|
|
17 Nov 2023
|
Tata Chemicals
|
Geojit BNP Paribas
|
925.30
|
868.00
|
963.40
(-3.95%)
|
|
Sell
|
|
|
|
|
11 Nov 2023
|
Tata Chemicals
|
Motilal Oswal
|
925.30
|
920.00
|
963.95
(-4.01%)
|
|
Neutral
|
|
|
|
|
05 May 2023
|
Tata Chemicals
|
ICICI Direct
|
925.30
|
1130.00
|
959.50
(-3.56%)
|
Target met |
Buy
|
|
|
|
|
06 Mar 2023
|
Tata Chemicals
|
Geojit BNP Paribas
|
925.30
|
1197.00
|
1002.05
(-7.66%)
|
|
Buy
|
|
|
|
|
03 Feb 2023
|
Tata Chemicals
|
ICICI Direct
|
925.30
|
1170.00
|
969.95
(-4.60%)
|
|
Buy
|
|
|
|
|
02 Feb 2023
|
Tata Chemicals
|
Motilal Oswal
|
925.30
|
1010.00
|
967.25
(-4.34%)
|
Target met |
Neutral
|
|
|
|
|
29 Oct 2022
|
Tata Chemicals
|
ICICI Direct
|
925.30
|
1345.00
|
1131.95
(-18.26%)
|
|
Buy
|
|
|
|
|
17 Aug 2022
|
Tata Chemicals
|
Geojit BNP Paribas
|
925.30
|
1340.00
|
1101.25
(-15.98%)
|
|
Buy
|
|
|
|
|
12 Aug 2022
|
Tata Chemicals
|
ICICI Direct
|
925.30
|
1370.00
|
1118.90
(-17.30%)
|
|
Buy
|
|
|
|
|
05 May 2022
|
Tata Chemicals
|
Geojit BNP Paribas
|
925.30
|
1196.00
|
1032.50
(-10.38%)
|
Target met |
Buy
|
|
|
|
|
02 May 2022
|
Tata Chemicals
|
ICICI Direct
|
925.30
|
1155.00
|
1033.00
(-10.43%)
|
Target met |
Buy
|
|
|
|
|
01 May 2022
|
Tata Chemicals
|
Motilal Oswal
|
925.30
|
1045.00
|
1033.00
(-10.43%)
|
Target met |
Neutral
|
|
|
|
|
13 Feb 2022
|
Tata Chemicals
|
Motilal Oswal
|
925.30
|
940.00
|
885.80
(4.46%)
|
Target met |
Neutral
|
|
|
Revenue and EBITDA in line, PAT higher the expected on a surge in JV profit Consolidated EBITDA came in line with our estimate, with a better than expected operating performance in India and the UK. However, a subdued operating performance in North America and Africa partially offsets growth. Globally, demand for Soda Ash has picked up significantly, resulting in a tight demand-supply situation. Spot prices have correspondingly increased, which will benefit TTCH. The challenging environment of increasing input costs (energy and freight) is likely to persist....
|
|
11 Feb 2022
|
Tata Chemicals
|
ICICI Securities Limited
|
925.30
|
1035.00
|
914.70
(1.16%)
|
Target met |
Hold
|
|
|
Q3FY22 Results: Topline was marginally above while bottomline beat was due to better-than-expected JV performance (Immacid) and lower taxes. Reported revenue growth of 21% YoY to | 3141.6 crore, led by higher...
|